Anaphylaxis News

Healio has compiled August’s most-read news in asthma and allergy.

SAN ANTONIO — Recently updated practice parameters will help clinicians better recognize and treat anaphylaxis, Jeffrey Demain, MD, FAAAAI, FACAAI, FAAP, told Healio at the 16th Annual Allergy, Asthma & Immunology CME Conference.

The European Commission has approved EURneffy for the emergency treatment of allergic reactions, according to a press release by ARS Pharmaceuticals, producer of the drug.

Advocates were pleased to learn about the FDA’s approval of ARS Pharmaceuticals’ neffy epinephrine nasal spray, which may have a significant impact on the safety and quality of life of families with allergy.

The FDA has approved neffy epinephrine nasal spray for emergency treatment of Type 1 allergic reactions, including anaphylaxis, in pediatric and adult individuals weighing at least 66 pounds.

A recent study published in the European Journal of Allergy and Clinical Immunology shows that significant cross-reactivity may exist between lupin and other legumes.

Healio has compiled July’s most-read news in asthma and allergy.

Giving young children an epinephrine autoinjection can be a positive and confidence-boosting experience for families, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Modified criteria that incorporated symptoms specific to infants and young children increased identification of anaphylaxis in these age groups, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

A dry powder epinephrine delivered via a nasal spray yielded drug exposures that were equal to or higher than those achieved through autoinjector in a canine model, according to the results of a study performed by Belhaven Biopharma.